2021 ISAKOS Biennial Congress ePoster
Comparison Of Bone Marrow Aspirate Concentrate And Allogenic Human Umbilical Cord Blood Derived Mesenchymal Stem Cell Implantation On Chondral Defect Of Knee: Assessment Of Clinical And Magnetic Resonance Imaging Outcomes At 2-Year Follow-Up
Dong Jin Ryu, MD, PhD., Seoul KOREA, REPUBLIC OF
Myung Ku Kim, MD, Inchon KOREA, REPUBLIC OF
Yoon Sang Jeon, MD, Seoul KOREA, REPUBLIC OF
Won Hwan Kwon, MD KOREA, REPUBLIC OF
Yun Moon Jeon, MD, Incheon KOREA, REPUBLIC OF
Kyeuback Kwon, MD, Osan-Si, Gyeonggi-do KOREA, REPUBLIC OF
Inha University Hospital, Incheon, Incheon, KOREA, REPUBLIC OF
The FDA has not cleared the following pharmaceuticals and/or medical device for the use described in this presentation. The following pharmaceuticals and/or medical device are being discussed for an off-label use: Medipost, Cartistem (approved by KFDA)
Summary
Implantation of MSCs from BMAC or hUCB-MSCs is safe and effective for repairing cartilage lesion.
ePosters will be available shortly before Congress
Abstract
Background
Biological repair of cartilage lesions remains a significant clinical challenge. A wide variety of methods involving mesenchymal stem cells (MSCs) have been introduced. Because of the limitation of the results, most of the treatment methods have not yet been approved by the Food and Drug Administration (FDA). However, bone marrow aspirate concentrate (BMAC) and human umbilical cord blood derived mesenchymal stem cells (hUCB-MSCs) implantation were approved by Korea FDA. The aim of this study was to evaluate clinical and magnetic resonance imaging (MRI) outcomes after two different types of MSCs implantation in knee osteoarthritis.
Methods
Fifty-two patients (52 knees) who underwent cartilage repair surgery using the BMAC (25 knees) and hUCB-MSCs (27 knees) were retrospectively evaluated for 2 years after surgery. Clinical outcomes were evaluated according to the score of visual analogue scale (VAS), the International Knee Documentation Committee (IKDC) subjective, and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Cartilage repair was assessed according to the modified Magnetic Resonance Observation of Cartilage Repair Tissue (M-MOCART) score and the International Cartilage Repair Society (ICRS) cartilage repair scoring system.
Results
At 2-year follow-up, clinical outcomes including VAS, IKDC, and KOOS sig- nificantly improved (P < 0.05) in both groups; however, there were no differences between two groups. There was no significant difference in M-MOCART [1-year (P = 0.261), 2-year (P = 0.351)] and ICRS repair score (P = 0.655) between two groups.
Conclusions
Both groups showed satisfactory clinical and MRI outcomes. Implantation of MSCs from BMAC or hUCB-MSCs is safe and effective for repairing cartilage lesion. However, large cases and a well-controlled prospective design with long-term follow-up studies are needed.